author-photo

Gracy Zacharian

University of Texas MD Anderson Cancer Center

7

Papers

395

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia

2017 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Addition of Rituximab Abrogates Ibrutinib-Induced Lymphocytosis and Promotes More Rapid Decrease in Absolute Lymphocyte Counts in Patients with Relapsed Chronic Lymphocytic Leukemia

2014 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

2014 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (291)
Ibrutinib In Combination With Rituximab (iR) Is Well Tolerated and Induces a High Rate Of Durable Remissions In Patients With High-Risk Chronic Lymphocytic Leukemia (CLL): New, Updated Results Of a Phase II Trial In 40 Patients

2013 Blood
Show All
- Source
- Cite
- Save
Citations (38)
The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients

2012 Blood
Show All
- Source
- Cite
- Save
Citations (48)
Phase I Study of Continuous-Infusion Nelarabine in Patients with Advanced Lymphoid Malignancies

2011 Blood
Show All
- Source
- Cite
- Save
Citations (8)